Publikationen von Sascha Young Kupke
Alle Typen
Meeting Abstract (3)
21.
Meeting Abstract
Single-cell analysis uncovers a novel influenza A virus-derived defective interfering particle for antiviral therapy. In Vaccine Technology VII, 133. Vaccine Technology VII, Mont Tremblant, Canada, 17. Juni 2018 - 22. Juni 2018. (2018)
Vortrag (29)
22.
Vortrag
Engineered defective interfering particles of influenza A virus for antiviral treatment. 33rd Annual Meeting of the Society for Virology (GfV), Vienna (Austria) (2024)
23.
Vortrag
Genetic engineering of Influenza A virus defective interfering particles towards improved antiviral efficacy and potential use as a live vaccine. Vaccine Technology IX, Los Cabos (Mexico) (2024)
24.
Vortrag
A two-dimensional model to predict influenza virus and defective interfering particle coinfection in tissue-like systems. 28th ESACT Meeting, Edingburgh (Scotland) (2024)
25.
Vortrag
Predicting the antiviral efficacy of defective interfering particles against influenza virus infection in tissues. KSMB-SMB 2024, Seoul (South Korea) (2024)
26.
Vortrag
Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 17th Vaccine Congress, Glasgow (Scotland) (2023)
27.
Vortrag
Reverse genetics for Influenza a virus to generate genetically engineered defective interfering particles for antiviral treatment and vaccination. Vir-AI-DIP Workshop , Hamburg (Germany) (2023)
28.
Vortrag
Absolute quantification of influenza A virus proteins during single-round replication in different host cells. 6th Workshop on Virus Dynamics, Nagoya (Japan) (2023)
29.
Vortrag
Influenza A virus defective interfering particles as antiviral agents. 32nd Annual Meeting of the Society for Virology (GfV), Ulm (Germany) (2023)
30.
Vortrag
Influenza A virus OP7 defective interfering particles: Cell culture-based production and antiviral efficacy in vivo. Cell Culture Engineering (CCE) XVIII , Cancun (Mexico) (2023)
31.
Vortrag
In-depth characterization and cell culture-based production of influenza A virus defective interfering particles. ACTIP fellowship session, Dublin (Ireland) (2023)
32.
Vortrag
Semi-continuous Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing the Dynamic Competition To Select Candidates for Antiviral Therapy. Vir-AI-DIP Workshop, Hamburg (Germany) (2023)
33.
Vortrag
OP7, a defective interfering particle with mutations: in vitro infection experiments, intracellular model, impact of mutations and mode of antiviral action. 6th Workshop on Virus Dynamics, Nagoya (japan) (2023)
34.
Vortrag
Multiscale model of influenza A virus and defective interfering particle co-infection in animal cell culture. Vir-AI-DIP Workshop, Hamburg (Germany) (2023)
35.
Vortrag
Production of influenza A virus defective interfering particles in a high cell density perfusion cultivation with continuous virus harvesting. Vaccine Technology VIII, Sitges (Spain) (2022)
36.
Vortrag
Influenza A Virus-Derived Defective Interfering Particles for Antiviral Treatment. 27th ESACT Meeting, Lisbon (Portugal) (2022)
37.
Vortrag
Influenza A Virus Defective Interfering Particles for Antiviral Treatment of the Influenza Disease and COVID-19. 31st Annual Meeting of the Society for Virology, online (2022)
38.
Vortrag
Long-Term Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing Dynamic Competition to Select Antiviral Candidates. Vaccine Technology VIII, Sitges (Spain) (2022)
39.
Vortrag
Semi-Continuous propagation of Influenza A virus and its defective interfering particles: Analyzing the dynamic competition to select antiviral candidates. 27th ESACT Meeting, Lisbon (Portugal) (2022)
40.
Vortrag
Modeling the intracellular replication of a new type of defective interfering particle of influenza virus with genomic nucleotide substitutions. 12th European Conference on Mathematical and Theoretical Biology, Heidelberg (Germany) (2022)